Research progress of immune checkpoint inhibitors in the treatment of lung cancer
10.3760/cma.j.cn371439-20201231-00135
- VernacularTitle:免疫检查点抑制剂在肺癌治疗中的研究进展
- Author:
Jun MA
1
;
Hongying ZHANG
;
Aiping WU
;
Guangyi GAO
Author Information
1. 南京中医药大学附属淮安中医院肿瘤科，淮安 223001
- Keywords:
Immunotherapy;
Lung neoplasms;
Immune checkpoint inhibitors
- From:
Journal of International Oncology
2021;48(11):683-687
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, immune checkpoint inhibitors are a milestone in the treatment of lung cancer. There are many kinds of immune checkpoints, which are closely related to the efficacy and drug resis-tance of immunotherapy, including programmed death-1 (PD-1), programmed death ligand-1 (PD-L1), cytotoxic T-lymphocyte antigen 4 (CTLA-4), killer cell immunoglobulin-like receptor (KIR), T cell immunoglobulin and ITIM domain (TIGIT), T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3), etc. PD-1/PD-L1 inhibitors have been approved by China National Medical Products Administration and U. S. Food and Drug Administration for the first-line treatment of lung cancer, which can improve overall survival and progression-free survival of patients. The double immunotherapies of CTLA-4 inhibitors or TIGIT inhibitors combined with PD-1/PD-L1 inhibitors also achieve good results, however, more serious adverse events may occur.The KIR and TIM-3 targets are closely related to the drug resistance of immunotherapy.
